Navigation Links
For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms

Lamictal Will Retain Decision Resources' Clinical Gold Standard Status for Bipolar Depression, According to a New Report from Decision Resources

WALTHAM, Mass., April 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists identify a therapy's effect on decrease in severity of depressive symptoms as the attribute that most influences their prescribing decisions in bipolar depression. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over AstraZeneca's Seroquel, the sales-leading agent in the market.

The new report entitled Bipolar Depression: Despite Negative Results, Physicians Still Hopeful About Aripiprazole also finds that an oral therapy that carries a lower risk of weight gain than Seroquel would earn a 21 percent patient share in bipolar depression in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European psychiatrists. The report also finds that, despite the failure of Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify (aripiprazole) in bipolar depression clinical trials, most interviewed thought leaders believe that Abilify is still an efficacious therapy for bipolar depression.

In 2008, Decision Resources' proprietary clinical gold standard for bipolar depression was lamotrigine (GlaxoSmithKline's Lamictal, generics). Based on available data and expert opinion, lamotrigine will retain gold standard status through 2017. While some therapies in development for bipolar depression hold promise, most have efficacy, safety and tolerability, and/or delivery features that are inferior when compared with lamotrigine.

"Owing to its efficacy and tolerability advantages, lamotrigine edged out Seroquel, its closest competitor, to become the clinical gold standard," said Decision Resources Analyst Sandra Chow, M.Sc. "Despite its slow onset of action, interviewed thought leaders were particularly impressed with lamotrigine's side-effect profile and better evidence of efficacy as a long term mood stabilizer."

About the Report

Bipolar Depression: Despite Negative Results, Physicians Still Hopeful About Aripiprazole is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563         

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New National Online Survey Says Bipolar Depressive Symptoms Have Impact on Day-To-Day Tasks as Well as Social Activities(1)
2. Repligen Licenses Patent Rights for Treatment of Bipolar Disorder
3. National Audience of Psychiatrists Assembling in Chicago for Conference on Bipolar Disorder and ADHD
4., the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
5. Kids Risks Increase When Parents Are Bipolar
6., the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder
7. AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
8. Common Genes Link Bipolar Disorder, Schizophrenia
9. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
10. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
11. Children of Older Fathers at Risk for Bipolar Disorder
Post Your Comments:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted ... as raising public awareness of the disorder while helping to bring expert medical ... $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at Ann & ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology: